Latest news with #RecursionOS
Associated Press
16-04-2025
- Business
- Associated Press
HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data
PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper insights into patient populations, enhanced trial design and feasibility assessments, as well as clinical operations workflows. By leveraging these high-quality, linked data assets, Recursion seeks to industrialize clinical development, reduce costs, and accelerate the development of novel therapeutics. 'Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials,' said Andrew Kress, CEO of HealthVerity. 'By providing seamless access to the industry's most comprehensive and interoperable real-world data, we empower innovators like Recursion to make data-driven decisions that streamline clinical development.' Recursion's proprietary AI-driven approach relies on integrating diverse datasets and AI/ML models to identify novel insights into human biology and molecule design. The incorporation of real-world data from HealthVerity Marketplace will further strengthen Recursion's ability to predict patient responses, refine study designs, and ensure clinical trial sites are positioned to meet enrollment goals. 'With the majority of the industry's time and resources focused on clinical trials, we see a significant opportunity to transform how clinical development is designed and executed,' said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. 'By integrating privacy-compliant real-world data from HealthVerity into Recursion OS, we are advancing our mission to optimize trial design through in silico simulations, accelerate recruitment through a patient-centric approach that includes underserved populations, and generate stronger evidence to inform development and regulatory decisions. By doing so, we are not only streamlining clinical development but also ensuring that we bring more impactful, life-changing treatments to patients faster and more efficiently' The HealthVerity approach to real-world data acquisition and governance ensures compliance with HIPAA and other regulatory frameworks while maintaining the highest standards of patient privacy. By combining data from the nation's largest healthcare data ecosystem, HealthVerity enables precise patient journey insights, supporting clinical development, regulatory submissions, and post-market studies. For more information, visit About HealthVerity HealthVerity is the leader in privacy-protected real-world data exchange, transforming how healthcare and life sciences organizations connect and analyze disparate patient data. By enabling access to the industry's largest RWD ecosystem, HealthVerity supports critical applications in clinical development, commercial strategy, and regulatory decision-making. About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world's largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, and chemistry to advance the future of medicine. Media Contact: HealthVerity [email protected] Recursion [email protected] View original content to download multimedia: SOURCE HealthVerity, Inc.
Yahoo
07-03-2025
- Business
- Yahoo
This Biotech Stock Could Be the Best Investment of the Decade
It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performance more. Identifying a stock that's likely to lead a marketwide charge for a decade is a different story. The organization in question must be able to offer something that's not only marketable for a long while, but also no other outfit can mimic. Such companies are relatively rare. There is one such stock to consider buying into sooner rather than later, though. That's a biotech company called Recursion Pharmaceuticals (NASDAQ: RXRX). And you can still plug into the ticker at a nice discount. Never heard of it? It would be a bit surprising if you had. Its market cap is a mere $3 billion, and it only did $58 million worth of business last year. And like many other young players in the biotechnology business, this one's also still booking sizable losses, adding to investors' general disinterest. What this company lacks in size and profits, though, it more than makes up for in potential. Just as the "Pharmaceuticals" in its name suggests, Recursion is a drug developer -- chiefly of therapies for more complicated (and expensive) ailments. For instance, its candidate REC-617 is being tested as a treatment for a number of difficult-to-treat solid tumors. REC-994 is being developed as a therapy for a condition called cerebral cavernous malformation, which can cause bleeding in the brain. Although both are in early-stage trials, given the lack of real alternatives, hopes for them and for the company's eight other pipeline candidates are high. It's not the drugs, however, that make Recursion such a compelling investment prospect. Rather, it's how these drugs were designed. The company is using its own proprietary artificial intelligence (AI) platform -- called Recursion OS -- to predesign and pretest these treatments, to determine the odds of success before committing time and money to a project. More importantly for interested investors, Recursion is now essentially sharing revenue-bearing access to this powerful software with other drug companies, creating a massive opportunity that's just now beginning to gel. It's not just an interesting business idea, to be clear. Major pharmaceutical names like Roche Holding, Bayer, Germany's Merck KGaA, Sanofi, and Rallybio are all on board, using Recursion OS to develop some of their next drugs. And well they should, given the time and cost involved in developing any new pharmaceutical and then getting it approved. Most estimates put the average cost at somewhere between $1 billion and $2 billion per drug, while the typical development time is in the ballpark of a decade. A lot can happen over that much time, and should a new drug fail in the latter stages of its trials, it can be an expensive misstep. Using a platform like Recursion OS, though, much of the cost-based risk can be sidestepped. The software also means drugmakers don't waste time, preventing competitors from developing an alternative drug in the meantime. And the difference is stark: With Recursion OS, what once required years and millions of dollars to figure out now only takes weeks and thousands of dollars. Perhaps even more promising is the fact that this biotechnological tool allows the pharmaceutical industry to investigate new research and development ideas that simply weren't possible to explore before. Industry research outfit Global Market Insights predicts the AI-powered drug discovery business will grow at an annualized pace of nearly 30% through 2032, jibing with a similar outlook from Straits Research. The underlying idea just holds too much promise to not pan out. Given the power of its proprietary platform and the sheer competitiveness and rising cost of being in the pharmaceutical business, Recursion is positioned to capture more than its fair share of this growth. That's the bullish argument. But if there's so much promise here, why is Recursion Pharmaceuticals' stock stuck near its record low, following a peak reached in mid-2021 soon after it went public? There's a perfectly good answer: Like so many other technology and biopharma stocks of its ilk and age, Recursion soared on hype before the world was fully ready to embrace its solution. Interest eventually waned -- ironically just shortly before the company became ready, willing, and able to deliver as promised. Analysts expect top-line growth of 75% this year, to be followed by sales growth of more than 37% next year. That still won't be enough to push the company out of the red, which may not happen for the next few years. A swing to a profit is on the radar within the next 10 years, however, and could be an explosive catalyst for the stock whenever it happens. Of course, simply making progress toward that finish line is likely to be good for the stock in the meantime, even if there's sure to be plenty of continued volatility between now and then. The analyst community's current consensus one-year price target stands at $8.60 per share, more than 30% above the present price. Just bear in mind that with this ticker's above-average potential reward, you'll get above-average risk. Manage it accordingly. Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $718,876!* Now, it's worth noting Stock Advisor's total average return is 873% — a market-crushing outperformance compared to 170% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of March 3, 2025 James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy. This Biotech Stock Could Be the Best Investment of the Decade was originally published by The Motley Fool
Globe and Mail
07-03-2025
- Business
- Globe and Mail
This Biotech Stock Could Be the Best Investment of the Decade
It's typically not too difficult to find a company that should perform well for the next couple of years. Two years isn't very long, after all, and the stock market's dynamics tend to dictate performance more. Identifying a stock that's likely to lead a marketwide charge for a decade is a different story. The organization in question must be able to offer something that's not only marketable for a long while, but also no other outfit can mimic. Such companies are relatively rare. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » There is one such stock to consider buying into sooner rather than later, though. That's a biotech company called Recursion Pharmaceuticals (NASDAQ: RXRX). And you can still plug into the ticker at a nice discount. What is Recursion Pharmaceuticals? Never heard of it? It would be a bit surprising if you had. Its market cap is a mere $3 billion, and it only did $58 million worth of business last year. And like many other young players in the biotechnology business, this one's also still booking sizable losses, adding to investors' general disinterest. What this company lacks in size and profits, though, it more than makes up for in potential. Just as the "Pharmaceuticals" in its name suggests, Recursion is a drug developer -- chiefly of therapies for more complicated (and expensive) ailments. For instance, its candidate REC-617 is being tested as a treatment for a number of difficult-to-treat solid tumors. REC-994 is being developed as a therapy for a condition called cerebral cavernous malformation, which can cause bleeding in the brain. Although both are in early-stage trials, given the lack of real alternatives, hopes for them and for the company's eight other pipeline candidates are high. It's not the drugs, however, that make Recursion such a compelling investment prospect. Rather, it's how these drugs were designed. The company is using its own proprietary artificial intelligence (AI) platform -- called Recursion OS -- to predesign and pretest these treatments, to determine the odds of success before committing time and money to a project. More importantly for interested investors, Recursion is now essentially sharing revenue-bearing access to this powerful software with other drug companies, creating a massive opportunity that's just now beginning to gel. The industry's ready to embrace such a solution It's not just an interesting business idea, to be clear. Major pharmaceutical names like Roche Holding, Bayer, Germany's Merck KGaA, Sanofi, and Rallybio are all on board, using Recursion OS to develop some of their next drugs. And well they should, given the time and cost involved in developing any new pharmaceutical and then getting it approved. Most estimates put the average cost at somewhere between $1 billion and $2 billion per drug, while the typical development time is in the ballpark of a decade. A lot can happen over that much time, and should a new drug fail in the latter stages of its trials, it can be an expensive misstep. Using a platform like Recursion OS, though, much of the cost-based risk can be sidestepped. The software also means drugmakers don't waste time, preventing competitors from developing an alternative drug in the meantime. And the difference is stark: With Recursion OS, what once required years and millions of dollars to figure out now only takes weeks and thousands of dollars. Perhaps even more promising is the fact that this biotechnological tool allows the pharmaceutical industry to investigate new research and development ideas that simply weren't possible to explore before. Industry research outfit Global Market Insights predicts the AI-powered drug discovery business will grow at an annualized pace of nearly 30% through 2032, jibing with a similar outlook from Straits Research. The underlying idea just holds too much promise to not pan out. Given the power of its proprietary platform and the sheer competitiveness and rising cost of being in the pharmaceutical business, Recursion is positioned to capture more than its fair share of this growth. Plenty of potential upside to justify the risk and volatility That's the bullish argument. But if there's so much promise here, why is Recursion Pharmaceuticals' stock stuck near its record low, following a peak reached in mid-2021 soon after it went public? There's a perfectly good answer: Like so many other technology and biopharma stocks of its ilk and age, Recursion soared on hype before the world was fully ready to embrace its solution. Interest eventually waned -- ironically just shortly before the company became ready, willing, and able to deliver as promised. Analysts expect top-line growth of 75% this year, to be followed by sales growth of more than 37% next year. That still won't be enough to push the company out of the red, which may not happen for the next few years. A swing to a profit is on the radar within the next 10 years, however, and could be an explosive catalyst for the stock whenever it happens. Of course, simply making progress toward that finish line is likely to be good for the stock in the meantime, even if there's sure to be plenty of continued volatility between now and then. The analyst community's current consensus one-year price target stands at $8.60 per share, more than 30% above the present price. Just bear in mind that with this ticker's above-average potential reward, you'll get above-average risk. Manage it accordingly. Should you invest $1,000 in Recursion Pharmaceuticals right now? Before you buy stock in Recursion Pharmaceuticals, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $718,876!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of March 3, 2025
